H
2552
vs
H
Hang Seng (Hong Kong)
Over the past 12 months, Hua Medicine has significantly outperformed Hang Seng (Hong Kong), delivering a return of +75% compared to the Hang Seng (Hong Kong)'s +21% growth.
Stocks Performance
2552 vs Hang Seng (Hong Kong)
Performance Gap
2552 vs Hang Seng (Hong Kong)
Performance By Year
2552 vs Hang Seng (Hong Kong)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Hua Medicine
Glance View
Hua Medicine Ltd. provides drug discovery and development services. The company is headquartered in Shanghai, Shanghai and currently employs 146 full-time employees. The company went IPO on 2018-09-14. The firm is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The firm mainly operates its business in the domestic and overseas markets.